Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.12T
Market cap1.12T
Price-Earnings ratio
41.92
Price-Earnings ratio41.92
Dividend yield
0.52%
Dividend yield0.52%
Average volume
2.39M
Average volume2.39M
High today
$1,239.30
High today$1,239.30
Low today
$1,180.01
Low today$1,180.01
Open price
$1,235.78
Open price$1,235.78
Volume
2.18M
Volume2.18M
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$712.05
52 Week low$712.05

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,193.83, giving the company a market capitalization of 1.12T. It carries a P/E multiple of 41.92 and pays a dividend yield of 0.52%.

On 2026-08-26, Eli Lilly(LLY) stock traded between a low of $1,180.01 and a high of $1,239.30. Shares are currently priced at $1,193.83, which is +1.2% above the low and -3.7% below the high.

The Eli Lilly(LLY)'s current trading volume is 2.18M, compared to an average daily volume of 2.39M.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

LLY News

Benzinga 46m
Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week

Eli Lilly and Co. (NYSE:LLY) shares are trading lower Wednesday, pulling back after the stock notched an all-time high just last week, even as the company separ...

Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week
TipRanks 3h
Lilly Quietly Expands Its Alzheimer’s Pipeline With New Early-Stage Trial

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Eli Lilly and Co. (LLY) has launched a Phase 1 trial titled “A Placebo-Control...

TipRanks 4h
Eli Lilly Stock in Focus as Alzheimer Blood Test Gets FDA Approval

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s (LLY) new blood test that helps to identify signs of Alzheimer’s disease in people aged 55...

Analyst ratings

82%

of 33 ratings
Buy
81.8%
Hold
12.1%
Sell
6.1%

More LLY News

Nasdaq 4h
Is It Too Late to Buy Eli Lilly? Billionaire Ken Griffin Doesn't Think So. He Nearly Quadrupled His Stake in the Pharma Stock in Q2.

Key Points Obesity drugs like Mounjaro and Zepbound could help the drugmaker power ahead for years. Its Alzheimer’s drug Kisunla and broad pipeline add anothe...

Is It Too Late to Buy Eli Lilly? Billionaire Ken Griffin Doesn't Think So. He Nearly Quadrupled His Stake in the Pharma Stock in Q2.
The Motley Fool 6h
Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus

The Fidelity MSCI Health Care Index ETF (FHLC +0.47%) provides broad, low-cost exposure to the entire healthcare sector, whereas the VanEck Pharmaceutical ETF (...

Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus
TipRanks 8h
Eli Lilly announces results from Zepbound healthcare costs study

Eli Lilly (LLY) announced results from a real-world study of adults over 55 with overweight or obesity, which found that staying on Zepbound for weight manageme...

Simply Wall St 16h
Eli Lilly Stock Trades Below Fair Value On Cash Flow

Eli Lilly stock has logged very strong gains over the past few years, yet the latest valuation checks send a mixed message about where fair value may sit. The i...

Eli Lilly Stock Trades Below Fair Value On Cash Flow
TipRanks 1d
Eli Lilly Stock Rattled as Companies Decline to Cover Weight-Loss Drug Costs

Beverage giant PepsiCo (PEP) is declining to cover the cost of weight-loss drugs for its employees. The news is a perceived blow to Eli Lilly (LLY) and has the...

TipRanks 1d
Lilly’s LY4395089 Interaction Study Marks Quiet but Important Early-Stage Progress

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) has completed a Phase 1 study titled “A Phase 1, O...

24/7 Wall St. 1d
Eli Lilly vs Novo Nordisk: One Winner in The Weight-Loss Drug Gold Rush

Eli Lilly vs Novo Nordisk: One Winner in The Weight-Loss Drug Gold Rush By Vandita Jadeja Published Aug 25, 10:30AM EDT Quick Read LLY posted 48% revenue grow...

Eli Lilly vs Novo Nordisk: One Winner in The Weight-Loss Drug Gold Rush

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.